Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Progen Pharmaceuticals Ltd Announces Non-Renounceable Rights Issue Share Allotment


Wednesday, 22 May 2013 01:28am EDT 

Progen Pharmaceuticals Ltd announced that it has completed an allotment and issue of 24,709,097 fully paid ordinary shares pursuant to its underwritten non-renounceable rights issue announced on April 16, 2013. The Company also issued 1,000,000 unlisted options to the Underwriter being part of the Rights Issue underwriting fee. The Options have an exercise price of $0.30 and expire on March 13, 2016 and were issued in accordance with the terms in the Underwriting Agreement dated March 15, 2013 as detailed in the Offer Document. The New Shares are expected to commence normal trading on the ASX on May 23, 2013. 

Company Quote

0.23
0.03 +15.00%
13 Aug 2014